Skip to main content
Equibles
ONC logo

ONC · BeOne Medicines Ltd.

Track ONC — free

Use ONC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ONC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$416.54 +0.58 (+0.14%) At close · Nov 13
Rebalance outlook locked
Market Cap
$47.58B
Shares
114.23M
Volume · Nov 13 345.46K Avg daily vol (3M) 404.68K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$416.54 Open$416.00 Day$412.28–417.14 52W close$260.27–424.00 Avg vol 30d434K Short int1.6M · 1.4% of shares · 4.4d Short vol55% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Next earnings call
Feb 25, 2027 Est · unconfirmed · in 15 wks
Q2 2026 earnings call transcript
call held Aug 5, 2026
Play latest call

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 34% to $1.9 billion

BeOne Medicines Ltd. reported third quarter 2026 total global revenues of $1.9 billion, up 34% versus third quarter 2025, as BRUKINSA revenue reached $1.4 billion, also up 34%. Diluted GAAP earnings per ADS were $3.28 and non-GAAP diluted earnings per ADS were $4.59.

Revenue $1.89B ▲ 33.8% Net income $384.71M ▲ 208.2% Diluted EPS $0.25 ▲ 212.5%
Read from the MD&A section
4 source passages
Effective May 27, 2025, we changed our jurisdiction of incorporation from the Cayman Islands to Switzerland through a transaction known as a continuation under Section 206 of the Companies Act (as amended) of the Cayman Islands and Article 161 of the Swiss Federal Act on Private International Law (the “Continuation”) and changed our legal English name from BeiGene, Ltd. to BeOne Medicines Ltd. Third quarter 2026 total global revenues increased 34% to $1.9 billion versus third quarter 2025 BRUKINSA® (zanubrutinib) global revenues increased 34% to $1.4 billion versus third quarter 2025 Diluted GAAP Earnings per American Depositary Share (“ADS”) of $3.28, non-GAAP diluted Earnings per ADS of $4.59. Open the document at this passage
Nov 5
Current report 8-K
Revenue rises 34% and 2026 guidance increases

BeOne Medicines Ltd. reported third-quarter total global revenues of $1.9 billion, up 34% from the prior year, and BRUKINSA (zanubrutinib) revenues of $1.4 billion, up 34%. It raised 2026 total revenue guidance to $6.9 to $7.0 billion.

Financial results
4 source passages
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior year Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$6.61B
Trailing 12 months
Net income (TTM)
$915.57M
Trailing 12 months
Revenue growth YoY
+33.8%
Year over year
Operating margin
17.8%
Trailing 12 months
P / E (TTM)
52.5
Trailing earnings · reciprocal yield 1.9%
FCF yield
3.0%
TTM · current market cap
Return on invested capital
85.7%
Trailing 12 months
Net cash
$4.71B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.4%
Year over year · more shares
Price change (1Y)
+13.1%
Trailing year
Short interest
1.4%
Latest settlement · 4.4 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲77.8% $1.13B −$151.88M '24 Q4* ▲48.6% $1.12B $1.27M '25 Q1 ▲41.6% $1.32B $94.32M '25 Q2 ▲41% $1.41B $124.84M '25 Q3 ▲32.8% $1.50B $66.50M '25 Q4* ▲35.5% $1.51B $227.36M '26 Q1 ▲29.6% $1.71B $237.01M '26 Q2 LATEST ▲33.8% $1.89B $384.71M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Strong Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +27%
above
Price vs 50-day avg +13%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 95%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +13%
trailing
6-month return +38%
trailing
YTD return +37%
this year
Relative strength +37%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $369 › 200d $328 — 50d above 200d
Institutional flow Accumulating
283 of 285 funds reported for Sep 30 · net +1.7M sh shares · +58 new
Insider flow Distributing
Net -$679.3K over 90 days · 100% sells
Short interest Falling
1.40% of shares out · ▼ -10.6% MoM · 4.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
285 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Excellent
Revenue growth +22179%
Y/Y
Gross margin 1961%
contracting
EPS growth +140%
Y/Y
Free cash flow $941.7M
Valuation P/E 682.9
rich
Balance sheet $3.5B
net cash
Quant / Vol
risk profile
Moderate
Volatility 34%
annualized · 1-yr
Max drawdown −31%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the 8-K filed Aug 5, 2026
GAAP operating expenses (combined R&D and SG&A) · full year 2026 Raised $4.8B – $5B
May 6, 2026 $4.7B – $4.9B changed to Aug 5, 2026 $4.8B – $5B
Non-GAAP operating income · full year 2026 Raised $1.7B – $1.8B
May 6, 2026 $1.45B – $1.55B changed to Aug 5, 2026 $1.7B – $1.8B
GAAP operating income · full year 2026 Raised $1B – $1.1B
May 6, 2026 $750M – $850M changed to Aug 5, 2026 $1B – $1.1B
Previous outlook earlier release · from the 8-K filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

Total revenue · Full Year 2026 $6.3B – $6.5B
Guided vs delivered · last 2 settled
Total Revenue Full Year 2025
guided $5B – $5.3B
$5.34B Beat +3.7%
Total revenue year ending December 31, 2021
guided $1.06B – $1.24B
$1.18B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+27% Bullish
Price vs 50-day avg
+13% Bullish
RSI (14)
67 Neutral
MACD trend
Positive Bullish
52-week position
95% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $369 › 200d $328 — 50d above 200d
Institutional flow Accumulating
283 of 285 funds reported for Sep 30 · net +1.7M sh shares · +58 new
Insider flow Distributing
Net -$679.3K over 90 days · 100% sells
Short interest Falling
1.40% of shares out · ▼ -10.6% MoM · 4.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
285 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $260 Now $417 · 95% Range high $424
vs 200-day avg +27% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted earnings per ADS - basic non-GAAP $7.37 Six Months Ended June 30, 2026 —
Adjusted earnings per ADS - diluted non-GAAP $7.08 Six Months Ended June 30, 2026 —
Adjusted earnings per share - basic non-GAAP $0.57 Six Months Ended June 30, 2026 —
Adjusted earnings per share - diluted non-GAAP $0.54 Six Months Ended June 30, 2026 —
Adjusted net income non-GAAP $819.54M Six Months Ended June 30, 2026 —
Free Cash Flow (Non-GAAP) non-GAAP $595.89M Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ONC
BeOne Medicines Ltd.
this stock
$47.58B +37.1% +22179.2% 682.9 1.4%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
322
% held
32.3%
Reported
283 of 285
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
140
View
Short & Settlement
Short Interest Falling
Shares short
1.6M
Days to cover
4.4d
Change
-190.3K sh
View
Short Volume
Short vol %
55%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
27.6K
Value
$10.1M
As of
Sep 29, 2026
View
Off-Exchange
Off-exchange %
58.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$679.3K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Jul 12, 2023
View
Financials
Financials
Revenue (FY)
$5.3B
Net income (FY)
$286.9M
EPS diluted
$0.19
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
23

BeOne Medicines Ltd. reported third-quarter total global revenues of $1.9 billion, up 34% from the prior year, and BRUKINSA (zanubrutinib) revenues of $1.4 billion, up 34%. It raised 2026 total revenue guidance to $6.9 to $7.0 billion.

View
Proposed Sales
Value
$632.3K
Shares
1.6K
Filed
Nov 6, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
BeOne Medicines Announces Third Q…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
ONC +2.4% +12.9% +37.7% +12.5% +37.1%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -0.2% +14.0% +37.2% +12.7% +26.5%
Key facts CIK 1651308 CUSIP 07725L102 13F (30d) 269 filings 245 filers Visit website Investor relations